Responses
Clinical/translational cancer immunotherapy
Original research
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases
Compose a Response to This Article
Other responses
No responses have been published for this article.